Maria Tsitskari

Percutaneous, computed tomography guided neurolysis using continuous radiofrequency for pain reduction in oncologic patients

Aim: This study evaluates the efficacy and safety of percutaneous computed tomography (CT)-guided neurolysis using continuous radiofrequency for pain reduction in oncologic patients. Methods: Over the course of 16 months, 22 patients underwent radiofrequency neurolysis as palliative therapy for pain reduction in celiac and splachnic plexus (n = 9), thoracic (n = 1), lumbar (n = 2) and superior hypogastric plexus (n = 5), as well as stellate ganglion (n = 5). Pain levels before treatment, one week after treatment, and at the last follow-up (average follow-up 6 months) were compared by means of a Numeric Visual Scale (NVS) questionnaire and a Brief Pain Inventory (Short Form) questionnaire. Results: Median procedure time was 44 min. Median number of CT scans, performed to control correct positioning of the cannula and precise electrode placement, was 8. Pain scores of questionnaires prior to treatment (mean value 9.50 NVS units, range 8-10 NVS units) and post treatment (mean value 3.27 NVS units, range 2-6 NVS units) showed a mean decrease of 6.23 NVS units in terms of pain reduction and life quality improvement (P < 0.05). Overall mobility improved in 18/18 (100%) patients. No complication was observed. Conclusion: This study concludes that CT-guided neurolysis by means of continuous radiofrequency ablation is a safe and efficient technique for pain palliation in oncologic patients.